XML 45 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]
A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited condensed consolidated statements of operations is as follows (in millions, except percentages):
Three Months Ended
September 30,		Nine Months Ended
September 30,
Net sales2020201920202019
MedSurg$825 $845$2,175 $2,429
Rhythm and Neuro757 7801,985 2,323
Cardiovascular1,002 1,0582,862 3,057
Total net sales of reportable segments2,584 2,6847,021 7,807
All other (Specialty Pharmaceuticals)74 23183 23
Consolidated net sales$2,659 $2,707$7,204 $7,831
Three Months Ended
September 30,		Nine Months Ended
September 30,
Income (loss) before income taxes2020201920202019
MedSurg$307 $319$738 $870
Rhythm and Neuro165 166296 488
Cardiovascular208 283593 860
Total operating income of reportable segments680 7681,628 2,218
All other (Specialty Pharmaceuticals)49 13124 13
Unallocated amounts:
Corporate expenses, including hedging activities(108)(75)(330)(215)
Intangible asset impairment charges, acquisition/divestiture-related net (charges) credits, restructuring- and restructuring-related net (charges) credits, EU MDR implementation costs and litigation-related net (charges) credits(629)(146)(957)(210)
Amortization expense(197)(178)(595)(498)
Operating income (loss)(205)383(130)1,308
Other expense, net(22)(292)(256)(615)
Income (loss) before income taxes$(227)$91$(386)$693
Operating income of reportable segments as a percentage of net sales of reportable segmentsThree Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
MedSurg37.2 %37.8 %33.9 %35.8 %
Rhythm and Neuro21.9 %21.3 %14.9 %21.0 %
Cardiovascular20.8 %26.7 %20.7 %28.1 %